Drug Trial Radar · NCT05330182
LMN-201 for Prevention of C. Difficile Infection Recurrence
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
375
Planned (sponsor's estimate)
Start
Aug 29, 2024
Primary completion
Aug 31, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Lumen Bioscience, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Congressionally Directed Medical Research Programs
- First posted
- Apr 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Conditions
- Clostridioides Difficile Infection
Interventions
LMN-201Drug
LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins: * 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile * 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism
PlaceboDrug
Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieve global cureTime frame: Up to 16 weeks after initiation of therapy
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Kaiser Permanente
Escondido, California
Gastroenterology Center of Connecticut
Hamden, Connecticut
University of South Florida
Tampa, Florida
Metro Infectious Disease Consultants, LLC
Burr Ridge, Illinois
Baptist Health Research
Lexington, Kentucky
Henry Ford Health System
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic - Rochester
Rochester, Minnesota
Weill Cornell Medicine
New York, New York
IMA Clinical Research
Mount Airy, North Carolina
MD Anderson Cancer Center
Houston, Texas
Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC
Annandale, Virginia
University of Virginia School of Medicine
Charlottesville, Virginia
Kaiser Permanente-Mid Atlantic
Springfield, Virginia
UW Health University Hospital
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.